EMEA-000371-PIP04-16
Key facts
| Invented name |
Revlimid
|
| Active substance |
lenalidomide
|
| Therapeutic area |
Oncology
|
| Decision number |
EMEA-000371-PIP04-16
|
| PIP number |
EMEA-000371-PIP04-16
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Celgene Europe Limited
Tel. +41 327298500
E-mail: medinfo.intl@celgene.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|